Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

BioLine Rx Q3 EPS $(0.01) May Not Be Comparable To $(0.21) Estimate

Author: Benzinga Newsdesk | November 20, 2023 08:02am
BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.21) by 95.24 percent. This is a 50 percent increase over losses of $(0.02) per share from the same period last year.

Posted In: BLRX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist